| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | poly(A) binding | 5.67e-05 | 29 | 8 | 2 | GO:0008143 | |
| GeneOntologyMolecularFunction | poly-purine tract binding | 9.29e-05 | 37 | 8 | 2 | GO:0070717 | |
| GeneOntologyMolecularFunction | single-stranded RNA binding | 8.39e-04 | 111 | 8 | 2 | GO:0003727 | |
| GeneOntologyMolecularFunction | mRNA binding | 2.05e-03 | 694 | 8 | 3 | GO:0003729 | |
| GeneOntologyMolecularFunction | mRNA 3'-UTR binding | 5.05e-03 | 276 | 8 | 2 | GO:0003730 | |
| GeneOntologyBiologicalProcess | mRNA metabolic process | 2.35e-04 | 917 | 8 | 4 | GO:0016071 | |
| GeneOntologyBiologicalProcess | mRNA splicing, via spliceosome | 2.72e-04 | 358 | 8 | 3 | GO:0000398 | |
| GeneOntologyBiologicalProcess | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 2.72e-04 | 358 | 8 | 3 | GO:0000377 | |
| GeneOntologyBiologicalProcess | RNA splicing, via transesterification reactions | 2.81e-04 | 362 | 8 | 3 | GO:0000375 | |
| GeneOntologyBiologicalProcess | regulation of mRNA metabolic process | 5.09e-04 | 443 | 8 | 3 | GO:1903311 | |
| GeneOntologyBiologicalProcess | RNA splicing | 7.33e-04 | 502 | 8 | 3 | GO:0008380 | |
| GeneOntologyBiologicalProcess | mRNA processing | 9.60e-04 | 551 | 8 | 3 | GO:0006397 | |
| GeneOntologyBiologicalProcess | mRNA destabilization | 2.67e-03 | 206 | 8 | 2 | GO:0061157 | |
| GeneOntologyBiologicalProcess | positive regulation of mRNA catabolic process | 2.80e-03 | 211 | 8 | 2 | GO:0061014 | |
| GeneOntologyBiologicalProcess | RNA destabilization | 2.80e-03 | 211 | 8 | 2 | GO:0050779 | |
| GeneOntologyBiologicalProcess | positive regulation of mRNA metabolic process | 4.18e-03 | 259 | 8 | 2 | GO:1903313 | |
| GeneOntologyBiologicalProcess | regulation of mRNA stability | 5.29e-03 | 292 | 8 | 2 | GO:0043488 | |
| GeneOntologyBiologicalProcess | regulation of RNA stability | 5.86e-03 | 308 | 8 | 2 | GO:0043487 | |
| GeneOntologyBiologicalProcess | regulation of mRNA catabolic process | 5.90e-03 | 309 | 8 | 2 | GO:0061013 | |
| GeneOntologyCellularComponent | spliceosomal complex | 5.78e-05 | 215 | 8 | 3 | GO:0005681 | |
| GeneOntologyCellularComponent | catalytic step 2 spliceosome | 5.86e-04 | 97 | 8 | 2 | GO:0071013 | |
| GeneOntologyCellularComponent | nuclear protein-containing complex | 1.06e-03 | 1377 | 8 | 4 | GO:0140513 | |
| GeneOntologyCellularComponent | chromatin | 1.39e-03 | 1480 | 8 | 4 | GO:0000785 | |
| GeneOntologyCellularComponent | ribonucleoprotein complex | 8.38e-03 | 1194 | 8 | 3 | GO:1990904 | |
| Domain | RRM_1 | 1.01e-06 | 208 | 8 | 4 | PF00076 | |
| Domain | RRM | 1.20e-06 | 217 | 8 | 4 | SM00360 | |
| Domain | RRM_dom | 1.43e-06 | 227 | 8 | 4 | IPR000504 | |
| Domain | RRM | 1.51e-06 | 230 | 8 | 4 | PS50102 | |
| Domain | HnRNP_R/Q_splicing_fac | 1.60e-06 | 5 | 8 | 2 | IPR006535 | |
| Domain | - | 1.91e-06 | 244 | 8 | 4 | 3.30.70.330 | |
| Domain | Nucleotide-bd_a/b_plait | 2.38e-06 | 258 | 8 | 4 | IPR012677 | |
| Pathway | WP_MRNA_PROCESSING | 3.35e-05 | 451 | 7 | 4 | MM15946 | |
| Pathway | WP_MRNA_PROCESSING | 1.62e-03 | 126 | 7 | 2 | M39406 | |
| Pathway | REACTOME_MRNA_SPLICING | 4.05e-03 | 201 | 7 | 2 | MM15411 | |
| Pathway | REACTOME_MRNA_SPLICING | 4.50e-03 | 212 | 7 | 2 | M14033 | |
| Pathway | REACTOME_PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA | 7.57e-03 | 277 | 7 | 2 | MM15414 | |
| Pathway | REACTOME_PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA | 7.89e-03 | 283 | 7 | 2 | M13087 | |
| Pubmed | 1.38e-08 | 421 | 8 | 5 | 34650049 | ||
| Pubmed | 5.28e-08 | 551 | 8 | 5 | 34728620 | ||
| Pubmed | CHD3 and CHD4 form distinct NuRD complexes with different yet overlapping functionality. | 8.40e-08 | 605 | 8 | 5 | 28977666 | |
| Pubmed | Heterogeneous nuclear ribonucleoproteins R and Q accumulate in pathological inclusions in FTLD-FUS. | 1.39e-07 | 3 | 8 | 2 | 30755280 | |
| Pubmed | 1.62e-07 | 244 | 8 | 4 | 29884807 | ||
| Pubmed | SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis through NSP9. | 2.02e-07 | 258 | 8 | 4 | 37794589 | |
| Pubmed | 2.09e-07 | 260 | 8 | 4 | 36199071 | ||
| Pubmed | 2.57e-07 | 274 | 8 | 4 | 34244482 | ||
| Pubmed | SMN interacts with a novel family of hnRNP and spliceosomal proteins. | 2.78e-07 | 4 | 8 | 2 | 11574476 | |
| Pubmed | 2.78e-07 | 4 | 8 | 2 | 11773003 | ||
| Pubmed | The mRNA-bound proteome and its global occupancy profile on protein-coding transcripts. | 3.51e-07 | 807 | 8 | 5 | 22681889 | |
| Pubmed | 6.09e-07 | 340 | 8 | 4 | 24332808 | ||
| Pubmed | 6.61e-07 | 347 | 8 | 4 | 16033648 | ||
| Pubmed | DBIRD complex integrates alternative mRNA splicing with RNA polymerase II transcript elongation. | 8.99e-07 | 89 | 8 | 3 | 22446626 | |
| Pubmed | 9.30e-07 | 90 | 8 | 3 | 23151878 | ||
| Pubmed | 9.30e-07 | 90 | 8 | 3 | 33087562 | ||
| Pubmed | MYC multimers shield stalled replication forks from RNA polymerase. | 9.60e-07 | 989 | 8 | 5 | 36424410 | |
| Pubmed | 1.30e-06 | 8 | 8 | 2 | 19808671 | ||
| Pubmed | 1.30e-06 | 8 | 8 | 2 | 12183049 | ||
| Pubmed | MECP2 directly interacts with RNA polymerase II to modulate transcription in human neurons. | 1.50e-06 | 1082 | 8 | 5 | 38697112 | |
| Pubmed | 1.95e-06 | 115 | 8 | 3 | 17332742 | ||
| Pubmed | 1.95e-06 | 115 | 8 | 3 | 20000738 | ||
| Pubmed | Systematic analysis of human protein complexes identifies chromosome segregation proteins. | 2.06e-06 | 1155 | 8 | 5 | 20360068 | |
| Pubmed | 2.27e-06 | 121 | 8 | 3 | 34029587 | ||
| Pubmed | LINKIN, a new transmembrane protein necessary for cell adhesion. | 2.40e-06 | 480 | 8 | 4 | 25437307 | |
| Pubmed | 2.54e-06 | 11 | 8 | 2 | 10734137 | ||
| Pubmed | RNF125 attenuates hepatocellular carcinoma progression by downregulating SRSF1-ERK pathway. | 2.54e-06 | 11 | 8 | 2 | 37142680 | |
| Pubmed | 2.69e-06 | 494 | 8 | 4 | 26831064 | ||
| Pubmed | 2.88e-06 | 131 | 8 | 3 | 28031328 | ||
| Pubmed | 3.05e-06 | 12 | 8 | 2 | 16236758 | ||
| Pubmed | 3.23e-06 | 136 | 8 | 3 | 26979993 | ||
| Pubmed | H4K20me0 recognition by BRCA1-BARD1 directs homologous recombination to sister chromatids. | 3.61e-06 | 1294 | 8 | 5 | 30804502 | |
| Pubmed | The PRMT5/WDR77 complex regulates alternative splicing through ZNF326 in breast cancer. | 4.08e-06 | 147 | 8 | 3 | 28977470 | |
| Pubmed | 6.29e-06 | 17 | 8 | 2 | 12388589 | ||
| Pubmed | 6.77e-06 | 174 | 8 | 3 | 32149426 | ||
| Pubmed | 7.22e-06 | 634 | 8 | 4 | 34591612 | ||
| Pubmed | PTPN14 regulates Roquin2 stability by tyrosine dephosphorylation. | 9.42e-06 | 678 | 8 | 4 | 30209976 | |
| Pubmed | Profiling of Parkin-binding partners using tandem affinity purification. | 1.07e-05 | 203 | 8 | 3 | 24244333 | |
| Pubmed | 1.12e-05 | 206 | 8 | 3 | 22174317 | ||
| Pubmed | 1.15e-05 | 713 | 8 | 4 | 29802200 | ||
| Pubmed | Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15. | 1.15e-05 | 714 | 8 | 4 | 28302793 | |
| Pubmed | 1.42e-05 | 223 | 8 | 3 | 20020773 | ||
| Pubmed | The E3 ubiquitin ligase HECTD1 contributes to cell proliferation through an effect on mitosis. | 1.47e-05 | 759 | 8 | 4 | 35915203 | |
| Pubmed | BioID-based Identification of Skp Cullin F-box (SCF)β-TrCP1/2 E3 Ligase Substrates. | 1.48e-05 | 226 | 8 | 3 | 25900982 | |
| Pubmed | A systems-wide screen identifies substrates of the SCFβTrCP ubiquitin ligase. | 1.60e-05 | 232 | 8 | 3 | 25515538 | |
| Pubmed | 1.88e-05 | 245 | 8 | 3 | 21182205 | ||
| Pubmed | PROTAC-mediated degradation reveals a non-catalytic function of AURORA-A kinase. | 1.93e-05 | 247 | 8 | 3 | 32989298 | |
| Pubmed | A Compendium of RNA-Binding Proteins that Regulate MicroRNA Biogenesis. | 2.10e-05 | 254 | 8 | 3 | 28431233 | |
| Pubmed | Interaction proteomics of the HMGA chromatin architectural factors. | 2.29e-05 | 32 | 8 | 2 | 18850631 | |
| Pubmed | Unbiased Identification of trans Regulators of ADAR and A-to-I RNA Editing. | 2.55e-05 | 271 | 8 | 3 | 32433965 | |
| Pubmed | 2.91e-05 | 36 | 8 | 2 | 17289661 | ||
| Pubmed | TNIP2 is a Hub Protein in the NF-κB Network with Both Protein and RNA Mediated Interactions. | 3.15e-05 | 922 | 8 | 4 | 27609421 | |
| Pubmed | The von Hippel-Lindau Cullin-RING E3 ubiquitin ligase regulates APOBEC3 cytidine deaminases. | 3.60e-05 | 40 | 8 | 2 | 34004371 | |
| Pubmed | The Nse5/6-like SIMC1-SLF2 complex localizes SMC5/6 to viral replication centers. | 3.61e-05 | 954 | 8 | 4 | 36373674 | |
| Pubmed | 3.86e-05 | 971 | 8 | 4 | 33306668 | ||
| Pubmed | NudCL2 regulates cell migration by stabilizing both myosin-9 and LIS1 with Hsp90. | 4.70e-05 | 333 | 8 | 3 | 32665550 | |
| Pubmed | Identifying biological pathways that underlie primordial short stature using network analysis. | 4.76e-05 | 1024 | 8 | 4 | 24711643 | |
| Pubmed | ARIH2 Is a Vif-Dependent Regulator of CUL5-Mediated APOBEC3G Degradation in HIV Infection. | 4.83e-05 | 336 | 8 | 3 | 31253590 | |
| Pubmed | Identification of DeltaNp63alpha protein interactions by mass spectrometry. | 5.19e-05 | 48 | 8 | 2 | 20085233 | |
| Pubmed | 5.27e-05 | 346 | 8 | 3 | 25324306 | ||
| Pubmed | 6.36e-05 | 1103 | 8 | 4 | 34189442 | ||
| Pubmed | 6.83e-05 | 55 | 8 | 2 | 31640799 | ||
| Pubmed | 7.12e-05 | 383 | 8 | 3 | 29331416 | ||
| Pubmed | Identification of a USP9X Substrate NFX1-123 by SILAC-Based Quantitative Proteomics. | 7.18e-05 | 384 | 8 | 3 | 31059266 | |
| Pubmed | Tumor suppressor BAP1 nuclear import is governed by transportin-1. | 7.46e-05 | 1149 | 8 | 4 | 35446349 | |
| Pubmed | 7.52e-05 | 390 | 8 | 3 | 17643375 | ||
| Pubmed | Regulation of error-prone translesion synthesis by Spartan/C1orf124. | 7.87e-05 | 59 | 8 | 2 | 23254330 | |
| Pubmed | Conserved expression of ultra-conserved noncoding RNA in mammalian nervous system. | 8.14e-05 | 60 | 8 | 2 | 29055695 | |
| Pubmed | 8.78e-05 | 411 | 8 | 3 | 36652389 | ||
| Pubmed | 9.69e-05 | 425 | 8 | 3 | 21081503 | ||
| Pubmed | TRIM28-mediated nucleocapsid protein SUMOylation enhances SARS-CoV-2 virulence. | 1.00e-04 | 430 | 8 | 3 | 38172120 | |
| Pubmed | C9orf72 protein quality control by UBR5-mediated heterotypic ubiquitin chains. | 1.06e-04 | 1257 | 8 | 4 | 37317656 | |
| Pubmed | Targeting USP10 induces degradation of oncogenic ANLN in esophageal squamous cell carcinoma. | 1.06e-04 | 1257 | 8 | 4 | 36526897 | |
| Pubmed | 1.08e-04 | 441 | 8 | 3 | 31239290 | ||
| Pubmed | New roles for the de-ubiquitylating enzyme OTUD4 in an RNA-protein network and RNA granules. | 1.24e-04 | 462 | 8 | 3 | 31138677 | |
| Pubmed | 1.30e-04 | 469 | 8 | 3 | 37314180 | ||
| Pubmed | 1.34e-04 | 1335 | 8 | 4 | 29229926 | ||
| Pubmed | Poly(ADP-ribosyl)ation of BRD7 by PARP1 confers resistance to DNA-damaging chemotherapeutic agents. | 1.44e-04 | 486 | 8 | 3 | 30940648 | |
| Pubmed | 1.45e-04 | 80 | 8 | 2 | 35803934 | ||
| Pubmed | 1.45e-04 | 80 | 8 | 2 | 11991638 | ||
| Pubmed | 1.49e-04 | 491 | 8 | 3 | 22623428 | ||
| Pubmed | 1.60e-04 | 503 | 8 | 3 | 36217030 | ||
| Pubmed | Gain of Additional BIRC3 Protein Functions through 3'-UTR-Mediated Protein Complex Formation. | 1.72e-04 | 1425 | 8 | 4 | 30948266 | |
| Pubmed | 1.74e-04 | 1429 | 8 | 4 | 35140242 | ||
| Pubmed | 1.75e-04 | 88 | 8 | 2 | 26318153 | ||
| Pubmed | 1.80e-04 | 1442 | 8 | 4 | 35575683 | ||
| Pubmed | 1.84e-04 | 90 | 8 | 2 | 31280863 | ||
| Pubmed | SPATA2 Links CYLD to LUBAC, Activates CYLD, and Controls LUBAC Signaling. | 2.17e-04 | 558 | 8 | 3 | 27591049 | |
| Pubmed | Proteomic dissection of the von Hippel-Lindau (VHL) interactome. | 2.18e-04 | 98 | 8 | 2 | 21942715 | |
| Interaction | RBM14 interactions | 1.11e-08 | 553 | 8 | 6 | int:RBM14 | |
| Interaction | TRIM31 interactions | 3.01e-07 | 454 | 8 | 5 | int:TRIM31 | |
| Interaction | FBXW11 interactions | 3.68e-07 | 473 | 8 | 5 | int:FBXW11 | |
| Interaction | CELF1 interactions | 2.73e-06 | 288 | 8 | 4 | int:CELF1 | |
| Interaction | DDX21 interactions | 2.90e-06 | 718 | 8 | 5 | int:DDX21 | |
| Interaction | CHD3 interactions | 3.76e-06 | 757 | 8 | 5 | int:CHD3 | |
| Interaction | FUS interactions | 3.76e-06 | 757 | 8 | 5 | int:FUS | |
| Interaction | GLDC interactions | 4.20e-06 | 321 | 8 | 4 | int:GLDC | |
| Interaction | BTRC interactions | 4.22e-06 | 775 | 8 | 5 | int:BTRC | |
| Interaction | WDR77 interactions | 6.70e-06 | 361 | 8 | 4 | int:WDR77 | |
| Interaction | MIRLET7D interactions | 6.72e-06 | 101 | 8 | 3 | int:MIRLET7D | |
| Interaction | RNF2 interactions | 7.28e-06 | 866 | 8 | 5 | int:RNF2 | |
| Interaction | MIRLET7E interactions | 7.77e-06 | 106 | 8 | 3 | int:MIRLET7E | |
| Interaction | MIRLET7I interactions | 9.67e-06 | 114 | 8 | 3 | int:MIRLET7I | |
| Interaction | PRMT1 interactions | 1.03e-05 | 929 | 8 | 5 | int:PRMT1 | |
| Interaction | MIRLET7G interactions | 1.05e-05 | 117 | 8 | 3 | int:MIRLET7G | |
| Interaction | CHD4 interactions | 1.08e-05 | 938 | 8 | 5 | int:CHD4 | |
| Interaction | HNRNPA1 interactions | 1.12e-05 | 945 | 8 | 5 | int:HNRNPA1 | |
| Interaction | DDX17 interactions | 1.29e-05 | 426 | 8 | 4 | int:DDX17 | |
| Interaction | KHDRBS2 interactions | 1.40e-05 | 129 | 8 | 3 | int:KHDRBS2 | |
| Interaction | SNRPC interactions | 1.46e-05 | 440 | 8 | 4 | int:SNRPC | |
| Interaction | UBE2S interactions | 1.72e-05 | 138 | 8 | 3 | int:UBE2S | |
| Interaction | IL7R interactions | 1.83e-05 | 141 | 8 | 3 | int:IL7R | |
| Interaction | DAZL interactions | 1.99e-05 | 145 | 8 | 3 | int:DAZL | |
| Interaction | SNRPA interactions | 2.10e-05 | 482 | 8 | 4 | int:SNRPA | |
| Interaction | COPS5 interactions | 2.36e-05 | 1102 | 8 | 5 | int:COPS5 | |
| Interaction | DHX15 interactions | 2.46e-05 | 502 | 8 | 4 | int:DHX15 | |
| Interaction | SNRPB interactions | 2.76e-05 | 517 | 8 | 4 | int:SNRPB | |
| Interaction | CPSF6 interactions | 2.95e-05 | 526 | 8 | 4 | int:CPSF6 | |
| Interaction | ITFG1 interactions | 3.28e-05 | 540 | 8 | 4 | int:ITFG1 | |
| Interaction | LSM4 interactions | 3.67e-05 | 178 | 8 | 3 | int:LSM4 | |
| Interaction | DDX5 interactions | 3.99e-05 | 568 | 8 | 4 | int:DDX5 | |
| Interaction | FAM20C interactions | 4.32e-05 | 188 | 8 | 3 | int:FAM20C | |
| Interaction | MECP2 interactions | 5.02e-05 | 1287 | 8 | 5 | int:MECP2 | |
| Interaction | RBM45 interactions | 5.76e-05 | 207 | 8 | 3 | int:RBM45 | |
| Interaction | NR4A1 interactions | 6.18e-05 | 212 | 8 | 3 | int:NR4A1 | |
| Interaction | BRD7 interactions | 6.25e-05 | 637 | 8 | 4 | int:BRD7 | |
| Interaction | CMTR1 interactions | 6.72e-05 | 218 | 8 | 3 | int:CMTR1 | |
| Interaction | U2AF2 interactions | 6.81e-05 | 651 | 8 | 4 | int:U2AF2 | |
| Interaction | MYCN interactions | 6.86e-05 | 1373 | 8 | 5 | int:MYCN | |
| Interaction | MATR3 interactions | 6.97e-05 | 655 | 8 | 4 | int:MATR3 | |
| Interaction | OASL interactions | 7.19e-05 | 223 | 8 | 3 | int:OASL | |
| Interaction | UBE2A interactions | 7.48e-05 | 226 | 8 | 3 | int:UBE2A | |
| Interaction | RC3H2 interactions | 7.49e-05 | 667 | 8 | 4 | int:RC3H2 | |
| Interaction | SSRP1 interactions | 8.30e-05 | 685 | 8 | 4 | int:SSRP1 | |
| Interaction | GAPDH interactions | 8.35e-05 | 686 | 8 | 4 | int:GAPDH | |
| Interaction | EED interactions | 8.77e-05 | 1445 | 8 | 5 | int:EED | |
| Interaction | TOP1 interactions | 8.84e-05 | 696 | 8 | 4 | int:TOP1 | |
| Interaction | SYNCRIP interactions | 1.01e-04 | 721 | 8 | 4 | int:SYNCRIP | |
| Interaction | LSM14A interactions | 1.13e-04 | 260 | 8 | 3 | int:LSM14A | |
| Interaction | SF3A2 interactions | 1.31e-04 | 273 | 8 | 3 | int:SF3A2 | |
| Interaction | METTL15 interactions | 1.32e-04 | 274 | 8 | 3 | int:METTL15 | |
| Interaction | MTRES1 interactions | 1.55e-04 | 289 | 8 | 3 | int:MTRES1 | |
| Interaction | DOT1L interactions | 1.57e-04 | 807 | 8 | 4 | int:DOT1L | |
| Interaction | MTIF3 interactions | 1.68e-04 | 297 | 8 | 3 | int:MTIF3 | |
| Interaction | MRRF interactions | 1.71e-04 | 299 | 8 | 3 | int:MRRF | |
| Interaction | GSPT1 interactions | 1.83e-04 | 306 | 8 | 3 | int:GSPT1 | |
| Interaction | RNF125 interactions | 1.88e-04 | 53 | 8 | 2 | int:RNF125 | |
| Interaction | HNRNPK interactions | 1.95e-04 | 853 | 8 | 4 | int:HNRNPK | |
| Interaction | ZNF169 interactions | 1.95e-04 | 54 | 8 | 2 | int:ZNF169 | |
| Interaction | CDC5L interactions | 1.96e-04 | 855 | 8 | 4 | int:CDC5L | |
| Interaction | ARIH2 interactions | 1.98e-04 | 314 | 8 | 3 | int:ARIH2 | |
| Interaction | RBM42 interactions | 2.31e-04 | 331 | 8 | 3 | int:RBM42 | |
| Interaction | CAND1 interactions | 2.33e-04 | 894 | 8 | 4 | int:CAND1 | |
| Interaction | ILF3 interactions | 2.35e-04 | 896 | 8 | 4 | int:ILF3 | |
| Interaction | EWSR1 interactions | 2.46e-04 | 906 | 8 | 4 | int:EWSR1 | |
| Interaction | SF3A3 interactions | 2.50e-04 | 340 | 8 | 3 | int:SF3A3 | |
| Interaction | PAIP2 interactions | 2.66e-04 | 63 | 8 | 2 | int:PAIP2 | |
| Interaction | HNRNPA0 interactions | 2.70e-04 | 349 | 8 | 3 | int:HNRNPA0 | |
| Interaction | MTERF3 interactions | 2.82e-04 | 354 | 8 | 3 | int:MTERF3 | |
| Interaction | RALY interactions | 2.87e-04 | 356 | 8 | 3 | int:RALY | |
| Interaction | TNIP2 interactions | 2.97e-04 | 952 | 8 | 4 | int:TNIP2 | |
| Interaction | HNRNPDL interactions | 3.06e-04 | 364 | 8 | 3 | int:HNRNPDL | |
| Interaction | MIR138-1 interactions | 3.10e-04 | 68 | 8 | 2 | int:MIR138-1 | |
| Interaction | PRC1 interactions | 3.23e-04 | 973 | 8 | 4 | int:PRC1 | |
| Interaction | HNRNPAB interactions | 3.24e-04 | 371 | 8 | 3 | int:HNRNPAB | |
| Interaction | MIR9-3 interactions | 3.29e-04 | 70 | 8 | 2 | int:MIR9-3 | |
| Interaction | SNRNP70 interactions | 3.38e-04 | 984 | 8 | 4 | int:SNRNP70 | |
| Interaction | HECTD1 interactions | 3.38e-04 | 984 | 8 | 4 | int:HECTD1 | |
| Interaction | MIR29B2 interactions | 3.38e-04 | 71 | 8 | 2 | int:MIR29B2 | |
| Interaction | MIR140 interactions | 3.38e-04 | 71 | 8 | 2 | int:MIR140 | |
| Interaction | MIR122 interactions | 3.38e-04 | 71 | 8 | 2 | int:MIR122 | |
| Interaction | DCAF4 interactions | 3.42e-04 | 378 | 8 | 3 | int:DCAF4 | |
| Interaction | MIR29B1 interactions | 3.57e-04 | 73 | 8 | 2 | int:MIR29B1 | |
| Interaction | MIR18A interactions | 3.57e-04 | 73 | 8 | 2 | int:MIR18A | |
| Interaction | SMC5 interactions | 3.59e-04 | 1000 | 8 | 4 | int:SMC5 | |
| Interaction | MKRN2 interactions | 3.61e-04 | 385 | 8 | 3 | int:MKRN2 | |
| Interaction | SNRPF interactions | 3.61e-04 | 385 | 8 | 3 | int:SNRPF | |
| Interaction | MIR20A interactions | 3.67e-04 | 74 | 8 | 2 | int:MIR20A | |
| Interaction | MIR15A interactions | 3.77e-04 | 75 | 8 | 2 | int:MIR15A | |
| Interaction | NEDD8 interactions | 3.83e-04 | 393 | 8 | 3 | int:NEDD8 | |
| Interaction | MIR429 interactions | 3.87e-04 | 76 | 8 | 2 | int:MIR429 | |
| Interaction | MIR16-1 interactions | 3.87e-04 | 76 | 8 | 2 | int:MIR16-1 | |
| Interaction | MIR7-3 interactions | 3.87e-04 | 76 | 8 | 2 | int:MIR7-3 | |
| Interaction | MIR199A2 interactions | 3.87e-04 | 76 | 8 | 2 | int:MIR199A2 | |
| Interaction | MIR9-2 interactions | 3.97e-04 | 77 | 8 | 2 | int:MIR9-2 | |
| Interaction | MIR200A interactions | 3.97e-04 | 77 | 8 | 2 | int:MIR200A | |
| Interaction | MRPL58 interactions | 4.04e-04 | 400 | 8 | 3 | int:MRPL58 | |
| Interaction | MIR451A interactions | 4.08e-04 | 78 | 8 | 2 | int:MIR451A | |
| Interaction | MIR98 interactions | 4.08e-04 | 78 | 8 | 2 | int:MIR98 | |
| GeneFamily | RNA binding motif containing | 6.38e-07 | 213 | 7 | 4 | 725 | |
| Coexpression | GSE14769_UNSTIM_VS_240MIN_LPS_BMDM_UP | 2.38e-05 | 200 | 8 | 3 | M3507 | |
| Coexpression | FISCHER_DREAM_TARGETS | 1.15e-04 | 969 | 8 | 4 | M149 | |
| Coexpression | IKEDA_MIR1_TARGETS_UP | 1.16e-04 | 54 | 8 | 2 | MM927 | |
| Coexpression | IKEDA_MIR1_TARGETS_UP | 1.16e-04 | 54 | 8 | 2 | M2372 | |
| Coexpression | LIU_COMMON_CANCER_GENES | 1.58e-04 | 63 | 8 | 2 | M18694 | |
| Coexpression | BUSSLINGER_ESOPHAGEAL_EARLY_SUPRABASAL_CELLS | 2.48e-04 | 79 | 8 | 2 | M40003 | |
| Coexpression | SAKAI_CHRONIC_HEPATITIS_VS_LIVER_CANCER_UP | 2.67e-04 | 82 | 8 | 2 | M9224 | |
| Coexpression | GSE6259_33D1_POS_DC_VS_CD8_TCELL_UP | 8.33e-04 | 145 | 8 | 2 | M6758 | |
| Coexpression | SCHAEFFER_PROSTATE_DEVELOPMENT_6HR_UP | 1.01e-03 | 160 | 8 | 2 | M1346 | |
| Coexpression | GSE14415_NATURAL_TREG_VS_TCONV_UP | 1.01e-03 | 160 | 8 | 2 | M2976 | |
| Coexpression | GSE5589_WT_VS_IL10_KO_LPS_STIM_MACROPHAGE_180MIN_UP | 1.04e-03 | 162 | 8 | 2 | M6673 | |
| Coexpression | SCHAEFFER_PROSTATE_DEVELOPMENT_6HR_UP | 1.09e-03 | 166 | 8 | 2 | MM563 | |
| Coexpression | PASQUALUCCI_LYMPHOMA_BY_GC_STAGE_DN | 1.17e-03 | 172 | 8 | 2 | M17811 | |
| Coexpression | PASQUALUCCI_LYMPHOMA_BY_GC_STAGE_DN | 1.18e-03 | 173 | 8 | 2 | MM580 | |
| Coexpression | GSE37301_HEMATOPOIETIC_STEM_CELL_VS_RAG2_KO_NK_CELL_UP | 1.20e-03 | 174 | 8 | 2 | M8885 | |
| Coexpression | GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN | 1.29e-03 | 776 | 8 | 3 | M1107 | |
| Coexpression | XIE_TRASTUZUMAB_CARDIOTOXICITY_MMU_MIR_669C_3P_GENES | 1.32e-03 | 183 | 8 | 2 | MM17506 | |
| Coexpression | GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN | 1.38e-03 | 794 | 8 | 3 | MM982 | |
| Coexpression | GSE19772_CTRL_VS_HCMV_INF_MONOCYTES_AND_PI3K_INHIBITION_UP | 1.48e-03 | 194 | 8 | 2 | M7288 | |
| Coexpression | GSE29617_CTRL_VS_DAY3_TIV_FLU_VACCINE_PBMC_2008_UP | 1.51e-03 | 196 | 8 | 2 | M4928 | |
| Coexpression | GSE2770_TGFB_AND_IL4_VS_TGFB_AND_IL12_TREATED_ACT_CD4_TCELL_48H_DN | 1.51e-03 | 196 | 8 | 2 | M6111 | |
| Coexpression | GSE17974_1H_VS_72H_UNTREATED_IN_VITRO_CD4_TCELL_UP | 1.53e-03 | 197 | 8 | 2 | M4237 | |
| Coexpression | GSE3982_MAC_VS_BASOPHIL_DN | 1.54e-03 | 198 | 8 | 2 | M5498 | |
| Coexpression | GSE17721_POLYIC_VS_CPG_8H_BMDC_DN | 1.56e-03 | 199 | 8 | 2 | M3947 | |
| Coexpression | GSE12366_PLASMA_CELL_VS_NAIVE_BCELL_DN | 1.56e-03 | 199 | 8 | 2 | M3175 | |
| Coexpression | GSE17721_LPS_VS_GARDIQUIMOD_6H_BMDC_DN | 1.56e-03 | 199 | 8 | 2 | M4055 | |
| Coexpression | GSE39820_TGFBETA3_IL6_VS_TGFBETA3_IL6_IL23A_TREATED_CD4_TCELL_UP | 1.56e-03 | 199 | 8 | 2 | M5620 | |
| Coexpression | GSE41867_DAY6_EFFECTOR_VS_DAY30_EXHAUSTED_CD8_TCELL_LCMV_CLONE13_DN | 1.57e-03 | 200 | 8 | 2 | M9490 | |
| Coexpression | GSE17721_CTRL_VS_POLYIC_1H_BMDC_UP | 1.57e-03 | 200 | 8 | 2 | M3707 | |
| Coexpression | GSE27786_CD4_TCELL_VS_NKCELL_UP | 1.57e-03 | 200 | 8 | 2 | M4822 | |
| Coexpression | GSE17721_CTRL_VS_CPG_2H_BMDC_UP | 1.57e-03 | 200 | 8 | 2 | M3759 | |
| Coexpression | GSE24574_BCL6_HIGH_TFH_VS_TFH_CD4_TCELL_DN | 1.57e-03 | 200 | 8 | 2 | M8331 | |
| Coexpression | GSE41176_WT_VS_TAK1_KO_ANTI_IGM_STIM_BCELL_6H_UP | 1.57e-03 | 200 | 8 | 2 | M9942 | |
| Coexpression | GSE22103_UNSTIM_VS_GMCSF_AND_IFNG_STIM_NEUTROPHIL_UP | 1.57e-03 | 200 | 8 | 2 | M7789 | |
| Coexpression | GSE37301_COMMON_LYMPHOID_PROGENITOR_VS_CD4_TCELL_UP | 1.57e-03 | 200 | 8 | 2 | M8868 | |
| Coexpression | GSE22103_LPS_VS_GMCSF_AND_IFNG_STIM_NEUTROPHIL_DN | 1.57e-03 | 200 | 8 | 2 | M7791 | |
| Coexpression | GSE17721_LPS_VS_GARDIQUIMOD_1H_BMDC_DN | 1.57e-03 | 200 | 8 | 2 | M4041 | |
| Coexpression | GSE21063_WT_VS_NFATC1_KO_8H_ANTI_IGM_STIM_BCELL_DN | 1.57e-03 | 200 | 8 | 2 | M8278 | |
| Coexpression | GSE17721_POLYIC_VS_PAM3CSK4_12H_BMDC_DN | 1.57e-03 | 200 | 8 | 2 | M3841 | |
| Coexpression | HALLMARK_MYC_TARGETS_V1 | 1.57e-03 | 200 | 8 | 2 | M5926 | |
| Coexpression | GSE42724_MEMORY_VS_B1_BCELL_UP | 1.57e-03 | 200 | 8 | 2 | M9794 | |
| Coexpression | HALLMARK_G2M_CHECKPOINT | 1.57e-03 | 200 | 8 | 2 | M5901 | |
| Coexpression | GSE43956_WT_VS_SGK1_KO_TH17_DIFFERENTIATED_CD4_TCELL_DN | 1.57e-03 | 200 | 8 | 2 | M9628 | |
| Coexpression | BIDUS_METASTASIS_UP | 1.92e-03 | 221 | 8 | 2 | M15866 | |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_e14.5_ Genital tubercle M_emap-6706_M-vs-F_top274_274 | 9.27e-05 | 256 | 8 | 3 | gudmap_developingLowerUrinaryTract_e14.5_ Genital tubercle M_250_M-vs-F | |
| ToppCell | Globus_pallidus-Macroglia-POLYDENDROCYTE-P3-Tnr|Globus_pallidus / BrainAtlas - Mouse McCarroll V32 | 7.26e-07 | 107 | 8 | 3 | 60b272f5c89bea8a2714f870e18b7ac89a4a4bf6 | |
| ToppCell | Globus_pallidus-Macroglia-POLYDENDROCYTE-P3|Globus_pallidus / BrainAtlas - Mouse McCarroll V32 | 7.26e-07 | 107 | 8 | 3 | c41bc8810df67158f0ae9f6015c965a8ebd96965 | |
| ToppCell | Globus_pallidus-Macroglia-POLYDENDROCYTE-P3-Tnr-Polydendrocyte.Tnr.Cyth3_(Cyth3)|Globus_pallidus / BrainAtlas - Mouse McCarroll V32 | 2.13e-06 | 153 | 8 | 3 | 88ca2d2c2ab19fbee13e18951b993ee05dd30f67 | |
| ToppCell | Globus_pallidus-Macroglia-POLYDENDROCYTE-P3-Tnr-Polydendrocyte.Tnr.Cyth3_(Cyth3)-|Globus_pallidus / BrainAtlas - Mouse McCarroll V32 | 2.13e-06 | 153 | 8 | 3 | 553dff9688a1996d8f4ba16e60c683593d781389 | |
| ToppCell | Hippocampus-Macroglia-POLYDENDROCYTE-P5-P5_2-Sox4|Hippocampus / BrainAtlas - Mouse McCarroll V32 | 2.51e-04 | 136 | 8 | 2 | 0185486c39700dd2f72d79be6d283494dd8379c9 | |
| ToppCell | Hippocampus-Macroglia-POLYDENDROCYTE-P5-P5_2|Hippocampus / BrainAtlas - Mouse McCarroll V32 | 2.51e-04 | 136 | 8 | 2 | 3e13dc0634f3b05e9f9e6c3193f843f62e603b78 | |
| ToppCell | Hippocampus-Macroglia-POLYDENDROCYTE-P5|Hippocampus / BrainAtlas - Mouse McCarroll V32 | 4.39e-04 | 180 | 8 | 2 | 44988c34861df359a68376500c42a64fbcc4b431 | |
| ToppCell | Hippocampus-Macroglia-POLYDENDROCYTE|Hippocampus / BrainAtlas - Mouse McCarroll V32 | 4.78e-04 | 188 | 8 | 2 | 8bd6f2cd1aadbd6f9ed31b160f59c1eff144e1dc | |
| ToppCell | 10x5'v1-week_14-16-Lymphocytic_B-B_lineage|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 5.25e-04 | 197 | 8 | 2 | 7290f05d0b8465637420119941bcbf2fae44a7e4 | |
| ToppCell | 10x3'2.3-week_12-13-Lymphocytic_B-B_lineage-pre_B_progenitor|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 5.25e-04 | 197 | 8 | 2 | 106b0f9a0425facc634feb7498c9ba2c55edfbf8 | |
| ToppCell | 10x5'v1-week_14-16-Lymphocytic_B|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 5.25e-04 | 197 | 8 | 2 | 31dfd9842410b5c629f39b5130233995dceb0aef | |
| ToppCell | 10x3'2.3-week_12-13-Lymphocytic_B|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 5.36e-04 | 199 | 8 | 2 | cdee798e3586e4e7a15de598239090a85752ea1e | |
| ToppCell | 10x5'v1-week_12-13-Lymphocytic_B|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 5.36e-04 | 199 | 8 | 2 | 713dfd8552635645db5e0b5721c64e5c9b4aa06c | |
| ToppCell | 10x5'v1-week_12-13-Lymphocytic_B-B_lineage|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 5.36e-04 | 199 | 8 | 2 | ea75804c34989c99aab542e6d72617ed144819b6 | |
| ToppCell | megakaryocytic-CD34+_Megakaryoblast|megakaryocytic / Lineage and Cell class | 5.36e-04 | 199 | 8 | 2 | 99a65887d3c8a2cde26693dd74404b101bba9d58 | |
| ToppCell | 10x5'v1-week_12-13-Lymphocytic_B-B_lineage-pre_pro_B_progenitor|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 5.36e-04 | 199 | 8 | 2 | 5478b78349b5d8d57f30bb650dcbd5fdb84283d6 | |
| ToppCell | LPS_only|World / Treatment groups by lineage, cell group, cell type | 5.36e-04 | 199 | 8 | 2 | 852cf595c2255983cff9045f2bb746d4391cf5ba | |
| ToppCell | 10x3'2.3-week_12-13-Lymphocytic_B-B_lineage|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 5.36e-04 | 199 | 8 | 2 | fe3b7d540a644dfc6beea171c809b4d1ba4e188f | |
| ToppCell | Megakaryocytic-erythropoietic-Erythro-cells-Basophilic_Erythroblast|Megakaryocytic-erythropoietic / Lineage, cell class and subclass | 5.36e-04 | 199 | 8 | 2 | 6f159c1215439ec22374903124085746fa8da333 | |
| ToppCell | 10x5'v1-week_14-16-Lymphocytic_B-B_lineage-pre_pro_B_progenitor|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 5.36e-04 | 199 | 8 | 2 | 8daf945fc93169b0a4fa3ef9f4a87eedd52e314a | |
| ToppCell | 10x3'2.3-week_14-16-Lymphocytic_B-B_lineage|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 5.41e-04 | 200 | 8 | 2 | 0fd9a8730b7dc461ddf4586899d363541e72d8ba | |
| ToppCell | 10x5'v1-week_17-19-Lymphocytic_B|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 5.41e-04 | 200 | 8 | 2 | 364f09eb9ae4913f5c80a29e943e1c0b2ffd5f93 | |
| ToppCell | 10x3'2.3-week_14-16-Lymphocytic_B|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 5.41e-04 | 200 | 8 | 2 | 19a4213f180ac2d29625d140b602a93a74ab3fdd | |
| ToppCell | 10x5'v1-week_17-19-Lymphocytic_B-B_lineage|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 5.41e-04 | 200 | 8 | 2 | c28d4ca51d2e2a3a22784ee251975f16a55b0297 | |
| Computational | RNA splicing. | 4.17e-06 | 65 | 6 | 3 | MODULE_183 | |
| Computational | Neighborhood of DENR | 3.27e-04 | 51 | 6 | 2 | GNF2_DENR | |
| Computational | Neighborhood of SMC1L1 | 4.84e-04 | 62 | 6 | 2 | MORF_SMC1L1 | |
| Computational | Neighborhood of DDX5 | 5.00e-04 | 63 | 6 | 2 | GNF2_DDX5 | |
| Computational | Neighborhood of KPNB1 | 6.70e-04 | 73 | 6 | 2 | GNF2_KPNB1 | |
| Computational | Neighborhood of APEX1 | 1.06e-03 | 92 | 6 | 2 | GNF2_APEX1 | |
| Computational | Neighborhood of HDAC1 | 1.52e-03 | 110 | 6 | 2 | GNF2_HDAC1 | |
| Computational | Neighborhood of FBL | 2.65e-03 | 146 | 6 | 2 | GNF2_FBL | |
| Computational | Neighborhood of MYST2 | 3.66e-03 | 172 | 6 | 2 | GCM_MYST2 | |
| Drug | bromovanin | 9.30e-06 | 127 | 8 | 3 | ctd:C515564 | |
| Drug | Harmine hydrochloride [343-27-1]; Down 200; 16uM; MCF7; HT_HG-U133A | 2.78e-05 | 183 | 8 | 3 | 2750_DN | |
| Drug | Dilazep dihydrochloride [20153-98-4]; Down 200; 6uM; MCF7; HT_HG-U133A | 2.87e-05 | 185 | 8 | 3 | 4688_DN | |
| Drug | Acacetin [480-44-4]; Down 200; 14uM; MCF7; HT_HG-U133A | 3.20e-05 | 192 | 8 | 3 | 6044_DN | |
| Drug | 0175029-0000 [211245-78-2]; Down 200; 1uM; PC3; HT_HG-U133A | 3.46e-05 | 197 | 8 | 3 | 3694_DN | |
| Drug | 3-chlorobenzylamine | 4.36e-04 | 91 | 8 | 2 | CID000077802 | |
| Drug | poly(G | 6.82e-04 | 114 | 8 | 2 | CID000439502 | |
| Drug | AC1OCADI | 8.86e-04 | 130 | 8 | 2 | CID006914639 | |
| Drug | AC1L1AUZ | 1.29e-03 | 157 | 8 | 2 | CID000001160 | |
| Drug | Trichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A | 1.39e-03 | 163 | 8 | 2 | 5594_DN | |
| Drug | SAHA; Down 200; 10uM; MCF7; HT_HG-U133A_EA | 1.52e-03 | 171 | 8 | 2 | 1000_DN | |
| Drug | Trichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A_EA | 1.54e-03 | 172 | 8 | 2 | 1072_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A | 1.54e-03 | 172 | 8 | 2 | 4344_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A | 1.54e-03 | 172 | 8 | 2 | 4112_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A | 1.56e-03 | 173 | 8 | 2 | 4237_DN | |
| Drug | trichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A | 1.58e-03 | 174 | 8 | 2 | 6579_DN | |
| Drug | AC1NRA5C | 1.58e-03 | 174 | 8 | 2 | CID005287709 | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A | 1.58e-03 | 174 | 8 | 2 | 3462_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A | 1.58e-03 | 174 | 8 | 2 | 5693_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A | 1.58e-03 | 174 | 8 | 2 | 5065_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A | 1.61e-03 | 176 | 8 | 2 | 4632_DN | |
| Drug | resveratrol; Down 200; 10uM; MCF7; HT_HG-U133A_EA | 1.61e-03 | 176 | 8 | 2 | 958_DN | |
| Drug | trichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A | 1.61e-03 | 176 | 8 | 2 | 7499_DN | |
| Drug | trichostatin A ; Down 200; 1uM; MCF7; HT_HG-U133A_EA | 1.61e-03 | 176 | 8 | 2 | 981_DN | |
| Drug | trichostatin A ; Down 200; 1uM; MCF7; HT_HG-U133A_EA | 1.63e-03 | 177 | 8 | 2 | 873_DN | |
| Drug | Phenoxybenzamine hydrochloride [63-92-3]; Down 200; 11.8uM; PC3; HT_HG-U133A | 1.63e-03 | 177 | 8 | 2 | 4652_DN | |
| Drug | resveratrol; Down 200; 10uM; MCF7; HT_HG-U133A_EA | 1.63e-03 | 177 | 8 | 2 | 841_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A | 1.63e-03 | 177 | 8 | 2 | 6340_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A | 1.65e-03 | 178 | 8 | 2 | 4184_DN | |
| Drug | Trichostatin A, Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A_EA | 1.65e-03 | 178 | 8 | 2 | 1112_DN | |
| Drug | fisetin; Down 200; 50uM; PC3; HG-U133A | 1.65e-03 | 178 | 8 | 2 | 579_DN | |
| Drug | Trichostatin A, Streptomyces sp.; Down 200; 1uM; HL60; HT_HG-U133A | 1.67e-03 | 179 | 8 | 2 | 1175_DN | |
| Drug | trichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A | 1.67e-03 | 179 | 8 | 2 | 6910_DN | |
| Drug | trichostatin A; Down 200; 0.1uM; MCF7; HG-U133A | 1.67e-03 | 179 | 8 | 2 | 332_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A | 1.67e-03 | 179 | 8 | 2 | 5484_DN | |
| Drug | SAHA; Down 200; 10uM; HL60; HT_HG-U133A | 1.69e-03 | 180 | 8 | 2 | 2680_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A | 1.69e-03 | 180 | 8 | 2 | 4821_DN | |
| Drug | Etoposide [33419-42-0]; Down 200; 6.8uM; HL60; HG-U133A | 1.69e-03 | 180 | 8 | 2 | 1626_DN | |
| Drug | H-7 dihydrochloride; Down 200; 100uM; MCF7; HT_HG-U133A | 1.71e-03 | 181 | 8 | 2 | 5963_DN | |
| Drug | Chrysin [480-40-0]; Down 200; 15.8uM; HL60; HT_HG-U133A | 1.71e-03 | 181 | 8 | 2 | 3106_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HG-U133A | 1.72e-03 | 182 | 8 | 2 | 1891_DN | |
| Drug | trichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A | 1.76e-03 | 184 | 8 | 2 | 6916_DN | |
| Drug | Apigenin [520-36-5]; Down 200; 14.8uM; HL60; HT_HG-U133A | 1.76e-03 | 184 | 8 | 2 | 1321_DN | |
| Drug | Amoxicillin [26787-78-0]; Down 200; 11uM; MCF7; HT_HG-U133A | 1.78e-03 | 185 | 8 | 2 | 2620_DN | |
| Drug | Harmine hydrochloride [343-27-1]; Down 200; 16uM; MCF7; HT_HG-U133A | 1.78e-03 | 185 | 8 | 2 | 7209_DN | |
| Drug | 0175029-0000 [211245-78-2]; Down 200; 10uM; PC3; HT_HG-U133A | 1.80e-03 | 186 | 8 | 2 | 6875_DN | |
| Drug | Trichostatin A, Streptomyces sp.; Down 200; 1uM; HL60; HT_HG-U133A | 1.80e-03 | 186 | 8 | 2 | 2694_DN | |
| Drug | Sulfaphenazole [526-08-9]; Up 200; 12.8uM; PC3; HT_HG-U133A | 1.82e-03 | 187 | 8 | 2 | 1794_UP | |
| Drug | Cantharidin [56-25-7]; Down 200; 20.4uM; HL60; HT_HG-U133A | 1.82e-03 | 187 | 8 | 2 | 3075_DN | |
| Drug | Picrotoxinin [17617-45-7]; Down 200; 13.6uM; HL60; HT_HG-U133A | 1.84e-03 | 188 | 8 | 2 | 2161_DN | |
| Drug | Isoflupredone acetate [338-98-7]; Up 200; 9.6uM; PC3; HT_HG-U133A | 1.84e-03 | 188 | 8 | 2 | 1832_UP | |
| Drug | LY 294002; Down 200; 10uM; HL60; HT_HG-U133A | 1.84e-03 | 188 | 8 | 2 | 1177_DN | |
| Drug | resveratrol; Down 200; 50uM; MCF7; HG-U133A | 1.84e-03 | 188 | 8 | 2 | 595_DN | |
| Drug | LY 294002; Down 200; 10uM; MCF7; HT_HG-U133A_EA | 1.86e-03 | 189 | 8 | 2 | 1065_DN | |
| Drug | Apigenin [520-36-5]; Down 200; 14.8uM; MCF7; HT_HG-U133A | 1.86e-03 | 189 | 8 | 2 | 4401_DN | |
| Drug | Cloperastine hydrochloride [14984-68-0]; Down 200; 11uM; PC3; HT_HG-U133A | 1.86e-03 | 189 | 8 | 2 | 4271_DN | |
| Drug | 0175029-0000 [211245-78-2]; Down 200; 1uM; PC3; HT_HG-U133A | 1.86e-03 | 189 | 8 | 2 | 7392_DN | |
| Drug | 0173570-0000 [211245-44-2]; Down 200; 10uM; PC3; HT_HG-U133A | 1.86e-03 | 189 | 8 | 2 | 3690_DN | |
| Drug | LY 294002; Down 200; 10uM; MCF7; HT_HG-U133A_EA | 1.88e-03 | 190 | 8 | 2 | 1077_DN | |
| Drug | Luteolin [491-70-3]; Down 200; 14uM; MCF7; HT_HG-U133A | 1.88e-03 | 190 | 8 | 2 | 3379_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A | 1.88e-03 | 190 | 8 | 2 | 6709_DN | |
| Drug | Estradiol-17 beta [50-28-2]; Down 200; 14.6uM; PC3; HT_HG-U133A | 1.88e-03 | 190 | 8 | 2 | 6718_DN | |
| Drug | LY 294002; Down 200; 10uM; MCF7; HT_HG-U133A_EA | 1.88e-03 | 190 | 8 | 2 | 1074_DN | |
| Drug | Azacytidine-5 [320-67-2]; Down 200; 16.4uM; PC3; HT_HG-U133A | 1.88e-03 | 190 | 8 | 2 | 4010_DN | |
| Drug | N6-methyladenosine [1867-73-8]; Down 200; 14.2uM; HL60; HT_HG-U133A | 1.92e-03 | 192 | 8 | 2 | 1271_DN | |
| Drug | Spironolactone [52-01-7]; Down 200; 9.6uM; HL60; HG-U133A | 1.94e-03 | 193 | 8 | 2 | 1380_DN | |
| Drug | Etifenin [63245-28-3]; Down 200; 12.4uM; HL60; HT_HG-U133A | 1.94e-03 | 193 | 8 | 2 | 2477_DN | |
| Drug | Chrysin [480-40-0]; Down 200; 15.8uM; MCF7; HT_HG-U133A | 1.94e-03 | 193 | 8 | 2 | 6485_DN | |
| Drug | Zaprinast [37762-06-4]; Down 200; 14.8uM; PC3; HT_HG-U133A | 1.94e-03 | 193 | 8 | 2 | 6749_DN | |
| Drug | Pyrantel tartrate [33401-94-4]; Down 200; 11.2uM; PC3; HT_HG-U133A | 1.94e-03 | 193 | 8 | 2 | 5088_DN | |
| Drug | AG-028671 [847803-03-6]; Up 200; 10uM; MCF7; HT_HG-U133A | 1.94e-03 | 193 | 8 | 2 | 6587_UP | |
| Drug | trichostatin A; Down 200; 0.1uM; ssMCF7; HG-U133A | 1.94e-03 | 193 | 8 | 2 | 413_DN | |
| Drug | SC 19220; Up 200; 10uM; PC3; HT_HG-U133A | 1.96e-03 | 194 | 8 | 2 | 7065_UP | |
| Drug | Salsolinol hydrobromide [38221-21-5]; Down 200; 15.4uM; PC3; HT_HG-U133A | 1.96e-03 | 194 | 8 | 2 | 4232_DN | |
| Drug | 2-propylpentanoic acid; Down 200; 1000uM; PC3; HG-U133A | 1.96e-03 | 194 | 8 | 2 | 433_DN | |
| Drug | F0447-0125; Up 200; 10uM; MCF7; HT_HG-U133A | 1.96e-03 | 194 | 8 | 2 | 6424_UP | |
| Drug | Griseofulvin [126-07-8]; Down 200; 11.2uM; MCF7; HT_HG-U133A | 1.96e-03 | 194 | 8 | 2 | 2293_DN | |
| Drug | phenanthridinone; Down 200; 51.2uM; MCF7; HT_HG-U133A_EA | 1.96e-03 | 194 | 8 | 2 | 1115_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A | 1.96e-03 | 194 | 8 | 2 | 5017_DN | |
| Drug | Dichlorphenamide [120-97-8]; Down 200; 13.2uM; MCF7; HT_HG-U133A | 1.96e-03 | 194 | 8 | 2 | 3366_DN | |
| Drug | Procainamide hydrochloride [614-39-1]; Down 200; 14.8uM; PC3; HT_HG-U133A | 1.96e-03 | 194 | 8 | 2 | 4602_DN | |
| Drug | LY 294002; Down 200; 10uM; MCF7; HT_HG-U133A | 1.96e-03 | 194 | 8 | 2 | 6995_DN | |
| Drug | Acacetin [480-44-4]; Down 200; 14uM; MCF7; HT_HG-U133A | 1.98e-03 | 195 | 8 | 2 | 3942_DN | |
| Drug | 0393-0188; Up 200; 10uM; MCF7; HT_HG-U133A | 1.98e-03 | 195 | 8 | 2 | 7531_UP | |
| Drug | Cefoperazone dihydrate; Down 200; 5.8uM; MCF7; HT_HG-U133A | 1.98e-03 | 195 | 8 | 2 | 5424_DN | |
| Drug | Fursultiamine Hydrochloride [2105-43-3]; Down 200; 9.2uM; HL60; HT_HG-U133A | 1.98e-03 | 195 | 8 | 2 | 2929_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; HL60; HG-U133A | 1.98e-03 | 195 | 8 | 2 | 1561_DN | |
| Drug | Dipyridamole [58-32-2]; Down 200; 8uM; PC3; HG-U133A | 1.98e-03 | 195 | 8 | 2 | 1934_DN | |
| Drug | PNU-0251126 [267429-19-6]; Down 200; 10uM; MCF7; HT_HG-U133A | 2.00e-03 | 196 | 8 | 2 | 4711_DN | |
| Drug | Debrisoquin sulfate [581-88-4]; Up 200; 9uM; MCF7; HT_HG-U133A | 2.00e-03 | 196 | 8 | 2 | 5288_UP | |
| Drug | Mevalonic-D, L acid lactone [674-26-0]; Down 200; 30.8uM; HL60; HT_HG-U133A | 2.00e-03 | 196 | 8 | 2 | 2718_DN | |
| Drug | Paclitaxel [33069-62-4]; Down 200; 4.6uM; HL60; HG-U133A | 2.00e-03 | 196 | 8 | 2 | 2043_DN | |
| Drug | Chlorpromazine hydrochloride [69-09-0]; Down 200; 11.2uM; HL60; HT_HG-U133A | 2.00e-03 | 196 | 8 | 2 | 1864_DN | |
| Drug | Folic acid [59-30-3]; Down 200; 9uM; HL60; HG-U133A | 2.00e-03 | 196 | 8 | 2 | 1790_DN | |
| Drug | PNU-0293363 [326823-19-2]; Down 200; 10uM; PC3; HT_HG-U133A | 2.00e-03 | 196 | 8 | 2 | 6563_DN | |
| Drug | 9-deoxy-9-methylene-16,16-dimethyl Prostaglandin E2; Up 200; 10uM; MCF7; HT_HG-U133A | 2.00e-03 | 196 | 8 | 2 | 7552_UP | |
| Drug | radicicol; Up 200; 0.1uM; SKMEL5; HG-U133A | 2.00e-03 | 196 | 8 | 2 | 493_UP | |
| Drug | Edrophonium chloride [116-38-1]; Down 200; 19.8uM; PC3; HG-U133A | 2.00e-03 | 196 | 8 | 2 | 1936_DN | |
| Drug | Ethambutol dihydrochloride [1070-11-7]; Down 200; 14.4uM; MCF7; HT_HG-U133A | 2.00e-03 | 196 | 8 | 2 | 4120_DN | |
| Drug | Fluvastatin sodium salt [93957-55-2]; Down 200; 9.2uM; MCF7; HT_HG-U133A | 2.00e-03 | 196 | 8 | 2 | 5290_DN |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| GYENYNYYGAQNTSV | 31 | O43823 | |
| WNQGFNNYYDQGYGN | 346 | O14979 | |
| NNYYDQGYGNYNSAY | 351 | O14979 | |
| YNGFYYSNSANDQNL | 21 | Q96S86 | |
| SGNYGYKSENQEFYQ | 601 | O60506 | |
| SGNYGYNNDNQEFYQ | 611 | O43390 | |
| YNNDNQEFYQDTYGQ | 616 | O43390 | |
| DGYAQYAQYSQDYQQ | 366 | P52756 | |
| DNFGNYSDDNFGNYG | 146 | P61129 | |
| YYEGGNSQYGQQQDA | 321 | Q15532 |